More information: Astha Lamichhane et al, Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells, Oncotarget (2023). DOI: 10.18632/oncotarget.28517 ...

Send comments and news tips to [email protected]. Cite this: Novel Topical BRAF Inhibitor Shows Promise for Managing EGFR Inhibitor–Induced Acneiform Rash - Medscape - April 30, 2025.

In a genetic analysis of craniopharyngiomas, we found clonal BRAF V600E mutations in papillary craniopharyngiomas from 34 of 36 patients (94%), as well as activating beta-catenin (CTNNB1 ...

Several alterations of the BRAF gene can cause mutant forms of the BRAF protein to be made, leading to cancer development. V600 mutations – including V600E, V600K, and V600R – are common in ...

In cancer patients, BRAF-targeting precision therapeutics are effective against Class I BRAF alterations (p.V600 hotspot mutations) in tumors such as melanoma, thyroid cancer, and colorectal cancer.

C4 Therapeutics is continuing to saw off parts of its pipeline, this time ending work on its clinical-stage BRAF degraded program in order to focus on its IKZF1/3 degrader cemsidomide.

Case Studies > Oncology/Hematology BRAF Inhibition in Pediatric Ameloblastoma of the Jaw — Targeted therapy in 3 boys allowed for conservative surgery to restore jaw to predisease state by Kate ...

Background: BRAF mutations that occur outside of codon 600, non-V600 BRAF (non-V600BRAF), have been detected in various types of tumors. Prevalence, and prognostic impact remain underestimated Methods ...